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【Summary】 
Systemic symptoms such as the ectopic calcification, atrophy of skin and muscle, and 
impaired sexual function observed in chronic kidney diseases (CKD) have been reported 
to coincide with those observed in geriatric symptoms. Regarding the kidney, 
clinical/pathological characteristics in CKD patients also coincide with those in the aging 
kidney. These findings suggest common mechanisms in the development of both CKD 
and aging. Our investigation of aging factors associated with renal fibrosis in IgA 
nephropathy patients revealed a significant correlation between accumulation of cells 
with arrested cell cycle and decreased expression of Klotho protein. Because cell cycle 
arrest has a protective effect on organs in the acute phase, the proposed therapeutic target 
against the aging process is to maintain expression of Klotho protein. In addition, 
transforming growth factor (TGF)-β1 is recognized to play a central role in the 
development of renal fibrosis. However, TGF-β1 has also been reported to decrease 
expression of Klotho protein. In this report, we provide an interpretation of our new 
treatment strategy which involves controlling histone methylation. 
  
[Introduction]  
Chronic kidney disease (CKD) is estimated to have a global prevalence of 8% to 16%, 
and it is recognized as the third most common disease in Japan after hypertension and 
diabetes mellitus. Various primary diseases can cause CKD, but advancing age can also 
cause impairment of renal function, and increases the risk of developing acute kidney 
injury (AKI) and renal carcinoma (1). Even in healthy individuals, it is known that renal 
function decreases with age while the incidence of AKI and renal carcinoma increases, 
showing that CKD patients and the elderly have clinical characteristics in common. Renal 
fibrosis is a pathological finding common to all renal disease, and one of the typical 
pathological characteristics of aged kidneys is renal fibrosis, suggesting these conditions 
may share a common pathogenesis on the molecular level. 
Many factors have already been associated with aging, but basic research has tied the 
following from among those that increase or decrease with age, to the development of 
AKI and carcinomas, and renal fibrosis: DNA damage induced by oxidative stress, 
accumulation of cells in cell cycle arrest, and decreases in Klotho, an anti-aging protein 
(2). 
 
[DNA damage due to oxidative stress] 
Many organisms require oxygen to survive and maintain their life activities. However, 
some forms of oxygen are extremely unstable and change into reactive oxygen species 
which readily react with many substances. Reactive oxygen species cause peroxidation 
of lipids, protein degeneration, enzyme inactivation and DNA damage, and they are 
implicated in the progression of various diseases. 8-hydroxydeoxyguanosine (8-OHdG) 
is formed by hydroxylation of the 8 position in deoxyguanosine, one of the base 
components of DNA. This compound is used as a marker of DNA damage due to 
oxidative stress. With aging, 8-OHdG expression is enhanced, particularly in the kidneys 
and liver, suggesting that the kidneys are one of the organs easily affected by oxidative 
stress due to aging. In addition, the use of antioxidants has been shown effective in 
inhibiting 8-OHdG production, and improving renal fibrosis in a unilateral ureteral 
obstruction model (UUO) (3), while oxidative stress appears to be intricately related to 
the onset of AKI and cancer (4, 5). However, reactive oxygen species may also play a 
role in various physiological functions such as the regulation of intracellular 
communication, metabolism, and immune function. Before instituting any therapeutic 
interventions, we should first determine the types and amounts of any antioxidants present 
at the sites of injury, together with reactions taking place at these sites. 
 
[Accumulation of cell-cycle arrested cells] 
Most human somatic cells do not express telomerase, the enzyme that repairs telomeres, 
so with repeated mitosis, telomeres become shorter and smaller and eventually, the cell 
cycles stop, causing cell aging. Recently, it has been discovered that stress, in addition to 
shortening telomeres, can induce other forms of cell aging. This type of cell aging is 
unrelated to mitotic lifespan, and referred to as "stress-induced cell aging." During the 
acute phase, aging functions as a normal, protective, physiological mechanism that sets 
in when normal cells are stressed. However, when cells arrested in the chronic phase of 
the cell cycle accumulate, this not only enhances cellular sensitivity towards the next 
stressor, but humoral factors are secreted and have been implicated in causing organ 
dysfunction. In fact, when p16, which induces cell cycle arrest, is knocked-out in mice, 
acute phase renal fibrosis worsens in a UUO model, but the renal fibrosis observed during 
the chronic phase, produced 4 weeks after ischemic reperfusion injury, is attenuated (6,7). 
Moreover, p16 is known to be a cancer-inhibiting factor, but when fibroblasts in cell cycle 
arrest are cultured long-term with epithelial cells, these epithelial cells have been reported 
to become cancerous (8). This suggests that aging fibroblasts may be involved in the 
development of renal carcinomas in dialysis patients. Similarly, lung and liver fibrosis 
are known to contribute to the development of cancer, and fibroblasts in cell cycle arrest 
are known to be involved in this process as well. Cell cycle arrest may thus have organ-
protective effects while in the acute phase, but chronically, contributes to renal fibrosis 
progression, AKI, and cancer development. One of our future goals will be to determine 
the appropriate timing for a therapeutic intervention. 
 
[Expression of Klotho proteins] 
Klotho genes have been identified as genes responsible for spontaneous mutation mice 
that express a variety of aging symptoms (9). Mice with overexpression of Klotho genes, 
however, are known to have extended lifespans (10). The Klotho protein is expressed on 
the cell surface membrane of renal tubules and plays a role as a co-receptor for fibroblast 
growth factor 23 (FGF 23) which is known as a phosphorus diuretic hormone. Decreased 
expression of Klotho protein which accompanies decreased renal function, is important 
as a factor that can cause bone mineral abnormalities related to CKD. Interestingly, 
Klotho deficient mice are short-lived with a lifespan of about 8 weeks. They also show 
arterial calcification, ectopic calcification, osteoporosis, growth dysfunction, skin and 
muscle atrophy, sexual gland dysfunction, and other symptoms that are similar to those 
seen in patients with chronic renal failure. Since these symptoms can be alleviated 
through correction of hyperphosphatemia and hypervitaminosis D, the above symptoms 
may be considered a result of calcium, phosphorus, and vitamin D metabolism 
abnormalities. 
On the other hand, Klotho protein exists as secretory types into the blood and urinary 
system. Klotho protein inhibits insulin-like growth factor1 (IGF1) signals, and it has been 
reported that when expression of insulin receptor substrate (IRS)-1 is decreased in 
Klotho-deficient mice, not only is there an extension in lifespan, but the aforementioned 
arteriosclerosis and ectopic calcification also improve (10). Furthermore, Klotho proteins 
have recently been reported to inhibit intracellular phosphorus uptake, thus inhibiting 
transformation of vascular smooth muscle (11). When Klotho protein is administered to 
Klotho-deficient mice, calcification is inhibited without a change in phosphorus 
concentrations (12), suggesting that secretory Klotho proteins have physiological activity. 
Until now, administration of Klotho proteins and excessive expression of Klotho genes 
have shown organ-protective effects, whereas various experimental animal models have 
been used to prove that mice with heterogeneous deficiencies for Klotho-gene expression 
have aggravated organ damage. An even more surprising finding is that even in organs 
besides the kidneys that only express small amounts of Klotho, there are papers showing 
that Klotho protein expression does result in organ-protective effects (13). In this way, in 
addition to bone mineral metabolism, maintaining expression of the Klotho protein is vital 
in terms of its organ-protective activity.  
 
[Target to treat renal aging] 
Using renal biopsy tissue from IgA nephropathy, the most common form of chronic 
glomerulonephritis, we looked at 8-OHdG, p16, and Klotho protein expression and the 
relationship to renal interstitial fibrosis. Single regression analysis revealed that in 
addition to factors shown thus far to be associated with renal fibrosis such as age, body 
mass index (BMI), systolic blood pressure, and urinary protein content, there is a 
significant relationship with 8-OHdG, p16, and Klotho protein expression. Multiple 
regression analysis showed that aging and increased p16 expression, and decreased 
expression of Klotho protein are independently correlated to renal fibrosis (Table 1) (2). 
Based on these results, in renal biopsy samples taken from actual clinical practice, the 
findings strongly suggest molecules related to aging are involved in progressive CKD. 
As described above, intervention into cell cycle arrest is the result of avoiding stress and 
therefore, in practice, we must discover how to maintain Klotho protein expression and 
this will be our treatment target going forward. On the other hand, various stimuli have 
been reported to cause decreases in Klotho expression. In fact, we experienced a 
phenomenon where when we intervened in UUO mice resulting in improvement in renal 
fibrosis, Klotho protein expression in the kidneys did not improve (14). We need to 
elucidate the mechanism behind decreased Klotho expression and establish a treatment 
method. 
 
[The role of TGF-β1-Smad2/3 signals in the renal fibrosis process, and issues related to 
drug discovery] 
Renal fibrosis is the characteristic pathological feature common to CKD progress, so it is 
clear that transforming the growth factor (TGF)-β1-Smad2/3 signal is intricately involved 
in this process. However, as shown in Table 1, TGF-β1-Smad2/3 signal has anti-
inflammatory effects and so long-term inhibition of this signal pathway may induce 
severe systemic inflammation. As a matter of fact, TGF-β1 knockout mice may die due 
to severe inflammation after birth. We therefore need to develop a therapeutic agent that 
specifically inhibits just the effects of TGF-β1-Smad2/3 signal in promoting fibrosis.  
Renal fibrosis involves a process as follows: 1) loss properties of renal fibroblast, renal 
tubular cells, vascular endothelial cells, 2) transformation to muscle fibroblasts, 3) muscle 
fibroblast to extracellular matrix protein production, and in all of these, the TGF-β1-
Smad2/3 signal is known to play a role. If the effect of TGF-β1 is classified by 
transcription activity, the loss of cell properties can be classified as decreased 
transcription activity, while fibroblast property acquisition and extracellular matrix 
protein production can be classified as enhanced transcription activity. In inflammatory 
cells, inhibition of IL-2, IL-4, INF-γ expression by TGF-β1-Smad2/3 signal can be 
classified as inhibited transcription activity, while enhanced IL-10 expression can be 
classified as increased transcription activity. However, inhibition of transcription activity 
due to some kind of stimulation cannot be explained by the existing "stimulation--> 
transcription --> translation" central dogma, and so the transcription activity inhibition 
mechanism due to TGF-β1 stimulation must be elucidated.  
 
[Treatment of renal fibrosis through histone methyltransferase inhibition] 
Epigenetics has become a hot topic as a regulatory system for gene expression that is not 
dependent on changes in DNA base sequence. Epigenetics involves processes such as 
methylation of DNA, modification of the histone tail, and microRNA, but while DNA 
methylation and microRNA negatively regulate genetic expression, histone tail 
modification involves a process that both up- and down-regulates transcription activity. 
Among modifications to the histone tail, methylation of the histone tail is regulated by a 
specific enzyme and so there is a possibility that by regulating this process, it may be 
possible to separate these complex effects. As presented in Fig. 2, we succeeded in 
showing enhanced expression of H3K4 histone methyltransferase SET domain-
containing lysine methyltransferase 7/9 (SET7/9) that enhances genetic expression 
though TGF-β1 stimulation, and H3K9 histone methyltransferase G9a, which inhibits 
genetic expression. Furthermore, we proved that monomethylation of H3K4 and H3K9 is 
an important histone modification associated with renal fibrosis (Fig. 2) (15, 16). On the 
other hand, results have shown that expression of TGF-β1 immunosuppression requires 
enhanced expression of IL-10 through trimethylation of H3K4, while inhibited expression 
of IL-2 is due to H3K9 trimethylation, making it possible to distinguish TGF-β1's effects 
in promoting fibrosis from its immunosuppressive effects. 
 
[Epigenetics involvement in decreased expression of Klotho protein] 
Klotho expression is known to decrease when stimulated by inflammatory cytokines, 
reactive oxygen species, indoxyl sulfate, and TGF-β1, not only in in vivo studies 
involving aging or renal dysfunction models, but also in in vitro studies. This suggests 
that not only does Klotho expression decrease with renal tissue damage, but that an 
epigenetic mechanism may also be involved. 
The Klotho gene promoter region forms a GC-rich island. Methylation of this region 
regulates whether or not the cell expresses Klotho or not. However, it is not clear what 
regulates the methylation. Interestingly enough, reports say the degree of methylation 
correlates to the severity of CKD (17). Moreno et al. have shown that inflammatory 
cytokines cause nuclear factor (NF)-κB-dependent inhibition of Klotho expression that 
can be inhibited with the use of histone deacetylase inhibitor, suggesting acetylation of 
the histone tail may be involved in this process (18). Moreover, there are reports saying 
that in cancer cells, Klotho expression is regulated by modification of the H3K9 (19). We 
have actually confirmed the presence of a Klotho gene promoter region in areas regulated 
by monomethylation of the H3K9 and it is clear that histone modification is involved in 
maintaining Klotho expression (16). Binding to the 3`untranscribed region of microRNA-
339 and microRNA-556, is also reported to be an important mechanism in inhibiting 
Klotho expression, and we eagerly await elucidation of its role in renal disease (20). 
 
[In conclusion] 
We described our research findings as they relate to aging as a new, potential therapeutic 
target in renal fibrosis. As described above, we believe that aging is a progressive process 
that occurs as an extension of physiological function much like oxidative stress. 
Alternatively, it can be considered the result of protective mechanisms against stress, such 
as the accumulation of cells in cell cycle arrest. In addition, the significance of a decrease 
in Klotho expression due to various stimuli may be interpreted as a phosphorus retention 
mechanism against stress. Furthermore, progress in epigenetics research allows us to view 
disease from a novel perspective as enhanced or depressed transcription activity. It may 
prove to be a persuasive mechanism to explain the diversity of cytokines. In the future, 
we hope to see the development of drugs that regulate epigenetics as treatments for renal 
diseases. 
 
[Acknowledgement] 
This work was supported by the Grant-in-Aid for Scientific Research (KAKENHI) 
No.16K09610 (to S.D.) in Hiroshima University. 
[References] 
1) Anderson S, Eldadah B, Halter JB, et al: Acute kidney injury in older adults, J Am 
Soc Nephrol 22: 28-38, 2011 
2) Yamada K, Doi S, Nakashima A, et al: Expression of age-related factors during the 
development of renal damage in patients with IgA nephropathy, Clin Exp Nephrol 
19(5):830-837, 2015 
3) Pat B, Yang T, Kong C, et al: Activation of ERK in renal fibrosis after unilateral 
ureteral obstruction: modulation by antioxidants, Kidney Int 67: 931-943, 2005 
4) Shingu C, Koga H, Hagiwara S, et al: Hydrogen-rich saline solution attenuates renal 
ischemia-reperfusion injury.J Anesth, 24(4):569-574, 2010 
5) Miyake H, Hara I, Kamidono S, et al: Prognostic significance of oxidative DNA 
damage evaluated by 8-hydroxy-2'-deoxyguanosine in patients undergoing radical 
nephrectomy for renal cell carcinoma, Urology 64: 1057-1061, 2004 
6) Wolstein JM, Lee DH, Michaud J, et al: INK4a knockout mice exhibit increased 
fibrosis under normal conditions and in response to unilateral ureteral obstruction, Am J 
Physiol Renal Physiol 299(6):F1486-495, 2010 
7) Lee DH, Wolstein JM, Pudasaini B, et al: INK4a deletion results in improved kidney 
regeneration and decreased capillary rarefaction after ischemia-reperfusion injury, Am J 
Physiol Renal Physiol 302(1): F183-191, 2012. 
8) Parrinello S, Coppe JP, Krtolica A, et al: Stromal-epithelial interactions in aging and 
cancer: senescent fibroblasts alter epithelial cell differentiation, J Cell Sci 118: 485-496, 
2005 
9) Kuro-o M, Matsumura Y, Aizawa H, et al: Mutation of the mouse klotho gene leads 
to a syndrome resembling ageing, Nature 390: 45-51, 1997 
10) Kurosu H, Yamamoto M, Clark JD, et al: Suppression of aging in mice by the 
hormone Klotho, Science 16; 309(5742): 1829-1833, 2005 
11) Hu MC, Shi M, Zhang J, et al: Klotho deficiency causes vascular calcification in 
chronic kidney disease, J Am Soc Nephrol 22(1):124-136, 2011 
12) Chen TH, Kuro-O M, Chen CH, et al: The secreted Klotho protein restores 
phosphate retention and suppresses accelerated aging in Klotho mutant mice, Eur J 
Pharmacol 5(698):67-73, 2013 
13) Lim K, Lu TS, Molostvov G, Lee C, et al: Vascular Klotho deficiency potentiates 
the development of human artery calcification and mediates resistance to fibroblast 
growth factor 23, Circulation 8; 125(18): 2243-2255, 2012 
14) Doi S, Zou Y, Togao O, et al: Klotho inhibits transforming growth factor-beta1 
(TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice, J 
Biol Chem, 286: 8655-8665, 2011 
15) Sasaki K, Doi S, Nakashima A, et al: Inhibition of SET Domain-Containing Lysine 
Methyltransferase 7/9 Ameliorates Renal Fibrosis. J Am Soc Nephrol 27; 203-215, 
2016 
16) Irifuku T, Doi S, Sasaki K, et al. Inhibition of H3K9 histone methyltransferase G9a 
attenuates renal fibrosis and retains klotho expression. Kidney Int 89; 147-157, 2016 
17) Chen J, Zhang X, Zhang H, et al: Elevated Klotho promoter methylation is 
associated with severity of chronic kidney disease. PloS One 5;8(11):e79856, 2013 
18) Moreno JA, Izquierdo MC, Sanchez-Niño MD, et al: The inflammatory cytokines 
TWEAK and TNFα reduce renal klotho expression through NFκB, J Am Soc Nephrol 
22(7): 1315-1325, 2011 
19) Rubinek T, Shulman M, Israeli S, et al: Epigenetic silencing of the tumor suppressor 
klotho in human breast cancer, Breast Cancer Res Treat 133(2):649-657, 2012 
20) Mehi SJ, Maltare A, Abraham CR, et al: MicroRNA-339 and microRNA-556 
regulate Klotho expression in vitro, Age 36(1):141-149, 2014 
 
 
  
Table 1. Univariate and multivariate regression analyses of factors associated with 
interstitial fibrosis 
 
univariate regression 
 
multivariate regression  
  r P 
 
β P 95% CI 
Age, year 0.62 <0.0001  0.38 0.001 0.07 to 0.26 
BMI, kg/m
2
 0.27 0.025  -0.038 0.69 -0.41 to 0.27 
SBP, mmHg 0.36 0.002  0.086 0.37 -0.04 to 0.11 
Urinary protein,  
g/24 hour 0.36 0.002 
 0.14 0.17 -0.35 to 2.5 
8-OHdG 0.26 0.031  0.025 0.78 -0.40 to 0.53 
p16 0.52 <0.0001  0.24 0.016 0.14 to 1.3 
Klotho -0.56 <0.0001  -0.23 0.019 -1.2 to -0.096 
BMI, body mass index 
SBP, systolic blood pressure 
r, correlation coefficient 
R2 values were 0.57 (unadjusted) and 0.523 (adjusted) 
β, standardized β coefficient 
 
  
Figure Legends 
Figure 1. Molecular mechanism of TGF-β1-Smad2/3 signal inflammatory cytokine 
production. 
In inflammatory cells, TGF-β1-Smad2/3 signals inhibit expression of inflammatory 
cytokines such as IL-2, IL-4, and INF-γ, and are involved in a pathway related to 
enhanced expression of IL-10, a cytokine that inhibits inflammation.  
 
Figure 2. How Histone Methylation Affects Renal Fibrosis 
Unilateral Ureter Obstruction (UUO) mice and TGF-β1-induced histone methylated 
enzyme SET7/9 and G9a cause H3K4 monomethylation (H3K4me1) and M3K9 
monomethylation (H3K9me1). H3K4me1 produces extracellular matrix, while 
H3K9me1 is involved in loss properties of renal cells, and involved in decreasing 
expression of the Klotho protein.  
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